Contact Congress about H.R. 7871: MVP Act

Medicaid and Medicare could use more drug deals where payment depends on results. The bill sets price-reporting rules, adds legal protection for some payments, and asks for a federal study.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

MVP Act is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 7871: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill mainly affects state Medicaid programs, drug makers, Medicare, hospitals, and patients who need costly drugs. States would get clearer rules for outcome-based drug deals. Drug makers would get new price-reporting rules and possible legal protection for some payments. Patients could be affected if these rules change which expensive treatments states choose to cover or how fast they use these contracts.

Why this matters: Very expensive drugs can strain state budgets, and this bill gives Medicaid and Medicare clearer ways to pay based on results. It could make outcome-based drug deals easier to use. It may also change rebates, Medicare payments, and legal risk for drug makers and states. The bill does not guarantee lower prices or coverage for any patient.

Key provisions in H.R. 7871

• Drug makers could report more than one Medicaid “best price” for one drug. This applies only when the drug is sold through an outcome-based deal offered to every state Medicaid program.
• Medicaid would count some money or goods tied to missed patient results in the drug’s average manufacturer price. This includes refunds, rebates, free goods, and payments that are reduced or held back.
• Some drug contracts are paid in installments over time. For Medicaid’s average manufacturer price, the bill treats the full contract price as paid during the first payment period.
• Medicare Part B would leave some amounts out of its average sales price formula. This applies when those amounts are also left out of Medicaid’s average manufacturer price under the new rule, and the drug maker uses multiple best prices.
• The Secretary of Health and Human Services must write rules for the new Medicaid price calculations. The deadline is 180 days after the bill becomes law.

How Modern Action helps you take action on H.R. 7871

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 7871

What is H.R. 7871?

Medicaid and Medicare could use more drug deals where payment depends on results. The bill sets price-reporting rules, adds legal protection for some payments, and asks for a federal study.

How do I support or oppose H.R. 7871?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 7871?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on H.R. 7871?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.